Similar articles for PMID: 17368275

Year	Number of Results
1982	1
1991	1
1999	1
2000	2
2001	6
2002	3
2003	2
2004	3
2005	9
2006	13
2007	17
2008	35
2009	19
2010	4
2011	1
2012	1
2015	1
2019	1
2024	0

1

Safety considerations with fibrate therapy.

Davidson MH, Armani A, McKenney JM, Jacobson TA. Davidson MH, et al. Am J Cardiol. 2007 Mar 19;99(6A):3C-18C. doi: 10.1016/j.amjcard.2006.11.016. Epub 2006 Dec 8. Am J Cardiol. 2007. PMID: 17368275 Review.

2

Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.

Fazio S. Fazio S. Clin Ther. 2008 Feb;30(2):294-306. doi: 10.1016/j.clinthera.2008.02.004. Clin Ther. 2008. PMID: 18343268 Review.

3

Expert commentary: the safety of fibrates in lipid-lowering therapy.

Brown WV. Brown WV. Am J Cardiol. 2007 Mar 19;99(6A):19C-21C. doi: 10.1016/j.amjcard.2006.11.017. Epub 2006 Nov 29. Am J Cardiol. 2007. PMID: 17368273 Review.

4

The treatment of dyslipidemia--what's left in the pipeline?

Rau O, Zettl H, Popescu L, Steinhilber D, Schubert-Zsilavecz M. Rau O, et al. ChemMedChem. 2008 Feb;3(2):206-21. doi: 10.1002/cmdc.200700165. ChemMedChem. 2008. PMID: 17963209 Review.

5

Fibrate therapy: an update.

Remick J, Weintraub H, Setton R, Offenbacher J, Fisher E, Schwartzbard A. Remick J, et al. Cardiol Rev. 2008 May-Jun;16(3):129-41. doi: 10.1097/CRD.0b013e31816b43d3. Cardiol Rev. 2008. PMID: 18414184 Review.

6

Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.

Davidson MH. Davidson MH. Expert Opin Drug Saf. 2006 Jan;5(1):145-56. doi: 10.1517/14740338.5.1.145. Expert Opin Drug Saf. 2006. PMID: 16370963 Review.

7

Pharmacokinetic interactions between statins and fibrates.

Corsini A, Bellosta S, Davidson MH. Corsini A, et al. Am J Cardiol. 2005 Nov 7;96(9A):44K-49K; discussion 34K-35K. doi: 10.1016/j.amjcard.2005.08.007. Epub 2005 Oct 21. Am J Cardiol. 2005. PMID: 16291014

8

Fibrates: no ACCORD on their use in the treatment of dyslipidaemia.

Wierzbicki AS. Wierzbicki AS. Curr Opin Lipidol. 2010 Aug;21(4):352-8. doi: 10.1097/MOL.0b013e32833c1e74. Curr Opin Lipidol. 2010. PMID: 20625256 Review.

9

Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.

Terra SG, Francone OL, Contant CF, Gao X, Lewin AJ, Nguyen TT. Terra SG, et al. Am J Cardiol. 2008 Aug 15;102(4):434-9. doi: 10.1016/j.amjcard.2008.03.076. Epub 2008 May 22. Am J Cardiol. 2008. PMID: 18678301 Clinical Trial.

10

Managing dyslipidemia in chronic kidney disease.

Harper CR, Jacobson TA. Harper CR, et al. J Am Coll Cardiol. 2008 Jun 24;51(25):2375-84. doi: 10.1016/j.jacc.2008.03.025. J Am Coll Cardiol. 2008. PMID: 18565393 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

106 results

Results by year